FTC pledges to fight reverse payments in 2010
Antitrust officials in the US this week urged Congress to ban settlement agreements between generic and brand name drug companies, saying that they cost consumers $3.5 billion a year
The US Federal Trade Commission made the claim in a study presented at a press conference on Wednesday. Speaking to reporters, FTC chairman Jon Leibowitz called on Congress to adopt a provision as part of the US health care reform...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.